ANE

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Retrieved on: 
星期一, 一月 8, 2024
Conference, KAT, AACR, Food, Woman, IND, Breast cancer, FDA, ANE, KAT6A, SAN, Cell proliferation, Cancer, Pharmacokinetics, Investigational New Drug, KAT6B, Pharmaceutical industry

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced the selection of a development candidate for the Company’s program targeting KAT6, an epigenetic target that is dysregulated in breast cancer and other cancers. The compound, named OP-3136, is an orally bioavailable, potent KAT6A/B-selective inhibitor developed by Olema in collaboration with Aurigene Oncology.

Key Points: 
  • The compound, named OP-3136, is an orally bioavailable, potent KAT6A/B-selective inhibitor developed by Olema in collaboration with Aurigene Oncology.
  • “We are excited to advance our KAT6 program with the nomination of OP-3136 as a development candidate.
  • OP-3136 has the potential to become a new targeted therapy for breast cancer and other cancers,” said Dr. David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema Oncology.
  • OP-3136 is orally bioavailable in multiple non-clinical species with desirable pharmacokinetics and has demonstrated highly selective and potent activity against KAT6A and KAT6B versus other KAT family members.

Trinity Consultants Acquires Valcoustics Canada Ltd.

Retrieved on: 
星期二, 十二月 19, 2023
Partnership, Ecology, Consultant, Acquisition, ANE, Lightstone, Built environment, EHS, AWN, ASK, Water, History, Environment

DALLAS, Dec. 19, 2023 /PRNewswire/ -- Trinity Consultants, a leading global environmental consulting firm providing services and solutions in the built environment, EHS regulatory compliance, life sciences, and water and ecology markets, today announced its acquisition of Valcoustics Canada Ltd., a Toronto-based acoustical engineering firm. The company will operate within Trinity's built environment business, combining its acoustical capabilities with those that span North America (with Trinity's Cerami and Longman Lindsey acquisitions), Ireland (with the AWN acquisition), and Australia (with the ASK and ANE acquisitions) into one unified entity.

Key Points: 
  • DALLAS, Dec. 19, 2023 /PRNewswire/ -- Trinity Consultants, a leading global environmental consulting firm providing services and solutions in the built environment, EHS regulatory compliance, life sciences, and water and ecology markets, today announced its acquisition of Valcoustics Canada Ltd., a Toronto-based acoustical engineering firm.
  • Since its inception in 1954, Valcoustics has been lauded for acoustic design excellence in residential land use planning, environmental compliance, and architectural applications.
  • "Valcoustics shares our dedication to helping clients unearth hidden acoustic and technical possibilities and pursue practical solutions," said Jim Perry, managing director at Trinity Cerami.
  • To learn more about Trinity Consultants and its services and leadership team, visit https://www.trinityconsultants.com .

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Retrieved on: 
星期二, 十一月 7, 2023
Data Management, Biotechnology, Alternative Medicine, Technology, FDA, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Carboplatin, AACR, HCI, WES, Organoid, 2D, RNA, Cisplatin, Crown Bioscience International, Timeline, Doctor of Philosophy, KRAS, Senior, Sequence, Paclitaxel, RNA-Seq, NGS, Drug discovery, PDX, ANE, CTG, AR, Automation, Medical imaging, Vitro

This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Key Points: 
  • This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
  • Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology.
  • OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening.
  • The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX).

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Retrieved on: 
星期四, 十月 12, 2023
Cancer, Pharmacokinetics, KAT6A, Breast cancer, KAT, Breast, AACR, ER, KAT8, ESR1, Gene, SAN, ANE, KAT6B, KAT5, Cell proliferation, Conference, Poster, Pharmaceutical industry, Vaccine

The poster, titled “The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer”, describes the discovery and preclinical characterization of orally bioavailable, potent KAT6A and KAT6B-selective inhibitors developed by Olema in collaboration with Aurigene Oncology.

Key Points: 
  • The poster, titled “The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer”, describes the discovery and preclinical characterization of orally bioavailable, potent KAT6A and KAT6B-selective inhibitors developed by Olema in collaboration with Aurigene Oncology.
  • In KAT6-amplified and overexpressing breast cancer cell lines, Olema KAT6 compounds strongly inhibited cell proliferation whereas KAT6-low cell lines were insensitive to the compounds.
  • Olema KAT6 inhibitor compounds caused dose-dependent tumor growth inhibition and tumor regression comparable to or better than a positive-control patented KAT6 inhibitor.
  • Olema KAT6 inhibitor compounds demonstrate histone target engagement and efficacy, as well as synergism with palbociclib or palazestrant (OP-1250).

Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium

Retrieved on: 
星期二, 十月 10, 2023
Doctor of Philosophy, Therapy, Toxicity, Bone marrow, ANE, Neoplasm, CD4, Optimism, PDC, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics , a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced it will present data findings on its preclinical candidate, CBX-15 (alphalex™-MMAE) for the treatment of triple negative breast cancer in a poster session at the 35th AACR-NCI-EORTC (ANE) Symposium .

Key Points: 
  • NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics , a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced it will present data findings on its preclinical candidate, CBX-15 (alphalex™-MMAE) for the treatment of triple negative breast cancer in a poster session at the 35th AACR-NCI-EORTC (ANE) Symposium .
  • The event is taking place October 11-15, 2023, in Boston, Massachusetts.
  • “In this preclinical study, CBX-15 demonstrated anti-tumor activity and efficacy without toxicity,” said Vishwas Paralkar, PhD, Chief Scientific Officer, Cybrexa Therapeutics.
  • “These compelling data instill confidence and align with the Company’s strategy to progress CBX-15 to Phase 1 clinical trials in 1Q of 2024.

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

Retrieved on: 
星期五, 十月 13, 2023
Index, Incidence, HIV disease progression rates, Physician, Neoplasm, ROS1, AST, NSCLC, Brain, ORR, Toxic leukoencephalopathy, Caregiver, MTD, PK, Toxicity, Safety, Mutation, Half-life, Cancer, Nausea, FDA, RECIST, Harvard Medical School, Clinical trial, Trae Elston, History, Patient, EDT, Assistant, ANE, ALT, CNS, ALK, TRK, TKI, Medical imaging, Pharmaceutical industry, Vaccine, Nursing

CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced updated preliminary data from the Phase 1 dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. These data will be presented today at the 35th AACR-NCI-EORTC (ANE) Symposium in Boston, Massachusetts.

Key Points: 
  • Preliminary activity data as of the cut-off date were available from 51 heavily pre-treated response-evaluable NSCLC patients.
  • In the subset of 41 patients treated at dose levels of 50 mg QD or higher, the ORR was 44% (18/41).
  • The Phase 2 cohorts are intended to support potential registration in patients with ALK-positive NSCLC who are both lorlatinib-naïve and lorlatinib-treated.
  • In addition to the planned Phase 2 cohorts, Nuvalent intends to use these preliminary data in patients with heavily pre-treated ALK-positive NSCLC to guide discussions with physicians that will inform development strategies in TKI-naïve ALK-positive NSCLC.

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
星期三, 九月 20, 2023
Poster, AACR, ER, ANE, Breast, Cancer, Conference, SAN, Pharmaceutical industry

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.

Key Points: 
  • SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.
  • The poster, demonstrating the activity of Olema’s KAT6 inhibitors, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (ANE 2023) taking place October 11-15, 2023, in Boston, Massachusetts.
  • “We are delighted to share new data at ANE 2023 regarding Olema’s preclinical program focused on KAT6 inhibition, with novel, proprietary compounds demonstrating anti-tumor activity in a variety of ER+ breast cancer models,” said David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema Oncology.
  • “This new program aligns with our mission of discovering and developing new targeted therapies for women’s cancers and is complementary to our efforts focused on the late-stage development of palazestrant (OP-1250) in advanced or metastatic ER+/HER2- breast cancer.”
    Details of the ANE 2023 poster presentation are:

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Retrieved on: 
星期一, 九月 18, 2023
TKI, Webcast, Clinical trial, Disclosure, Cancer, ANE, Patient, NSCLC, Safety, CNS, ALK, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.

Key Points: 
  • The presentation marks the first disclosure of data characterizing the safety and clinical activity of NVL-655 from the Phase 1 dose-escalation portion of the ongoing ALKOVE-1 Phase 1/2 clinical trial evaluating NVL-655 in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.
  • The ALKOVE-1 clinical trial is continuing to enroll patients in the Phase 1 portion of the trial.
  • Nuvalent plans to host a conference call and webcast on October 13, 2023.
  • Details for the conference call will be provided at a future date and available on the Nuvalent website at www.nuvalent.com .

ANE Welcomes Kimberley Wilson as Regional VP, Operations & Carrier Management

Retrieved on: 
星期五, 十一月 18, 2022
Insurance, Professional Services, Wilson, Region, Chartered Property Casualty Underwriter, Administrative building of the North-Kazakhstan regional executive committee, Multimedia, ANE, Renaissance, Operation

Kimberley Wilson has joined the executive team of Agency Network Exchange (ANE) as its new Regional Vice President of Operations & Carrier Management.

Key Points: 
  • Kimberley Wilson has joined the executive team of Agency Network Exchange (ANE) as its new Regional Vice President of Operations & Carrier Management.
  • View the full release here: https://www.businesswire.com/news/home/20221118005326/en/
    Wilson was most recently with Keystone Insurers Group, where she served as Director of Agency Network Development.
  • Kimberley brings a tremendous amount of industry and network expertise to this role, said Elizabeth Schenk, Regional Executive Vice President of Agency Network Exchange.
  • Wilson said, Im thrilled to be joining ANE and Im already impressed with the organizations collaborative culture and its high caliber of talent.

Luckin Coffee Announces Corporate Governance Changes

Retrieved on: 
星期五, 五月 20, 2022
Knowledge, U.S. Securities and Exchange Commission, Financial compensation, Terminology, Adoption, Private Securities Litigation Reform Act, Mathematics, SEC, New, INSEAD, Investment, Audit committee, Cayman, China Europe International Business School, Board, Massachusetts Institute of Technology, ANE, Growth, Applied mathematics, GLOBE, Company, Coffee, Vanderbilt University, China Foreign Affairs University, Association, HKEX, Warburg Pincus, Dartmouth College, CFA, Senior, MBA, Annual report, OTC, Myers, LLP, Industry, Forward-looking statement, Chairperson, Board of directors, Goldman Sachs, Accountant, Fudan University, ESG, Security (finance), Management, Convenience food, COVID-19, Luckin Coffee, PRC, New York University

BEIJING, May 20, 2022 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced the adoption of new directorship term, the resignations of two directors (Mr. Wai Yuen Chong and Mr. Gang Wu) from its Board of Directors (“Board”) and the appointments of four new directors (Mr. Weihao (Michael) Chen, Mr. Jun Liu, Ms. Qianli Liu and Mr. Shaoqiang (Gary) Liu) to the Board, effective immediately.

Key Points: 
  • BEIJING, May 20, 2022 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (Luckin Coffee or the Company) (OTC: LKNCY) today announced the adoption of new directorship term, the resignations of two directors (Mr. Wai Yuen Chong and Mr.
  • I look forward to continuing to work with them to deliver value for all Luckin Coffee stakeholders, said Dr. Jinyi Guo, Chairman and Chief Executive Officer of Luckin Coffee.
  • Luckin Coffee (OTC: LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers.
  • Empowered by proprietary technologies, Luckin Coffee pursues its vision to build a world-class coffee brand and become a part of everyones daily life.